Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bempegaldesleukin + Nivolumab + TKI in Advanced mRCC
NCT04540705Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2020
- Primary completion
- Jan 2024
- Modality
- Cytokines & Interferons
- Countries
- 8
01
Overview
Phase 1, open-label trial of bempegaldesleukin in renal cell carcinoma (RCC) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Incidence of Adverse Events up to 2.5 years, Incidence of Serious Adverse Events up to 2.5 years and 4 more. Started Sep 2020; status: completed.
02
Drugs
bempegaldesleukin
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT04540705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04540705.